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Stem cells to grow cartilage
Replacement cartilage could be grown for trans-
plantation, following the conversion of human
embryonic cells into cartilage cells. The research
involved growing human embryonic stem cells with
chondrocytes, in Petri dishes in a specialised system
to encourage them to change into cartilage cells.
These were implanted in mice on a bioactive scaf-
fold for 35 days, removal of the scaffold yielded new
cartilage produced upon transplantation.
Dr. Arachana Vats, Consultant ENT Surgeon,
Imperial College, UK, told the IJS: ‘‘The current
challenge facing medicine is inherently one of its
own making - an increasingly ageing population and
the obvious sequelae of increasing biological life-
span. Also, both the disease process itself as well as
the therapeutic options that we implement result in
destruction and malformation of tissues. The main
problem is how to generate adequate numbers of
cells. Reconstructing an injured face is a prime
example of when the limitations of existing tech-
niques of restoration become apparent. Injuries and
diseases which affect cartilage account for in excess
of US$10 billion healthcare spending per year on
artificial joint replacements. With patients living
longer, one joint replacement is often not sufficient
to last the rest of their natural life. Also, with life
expectancy increasing, more patients are needing
these treatments. Cartilage is a highly specialised
tissue with very poor intrinsic repair capacity. The
ability to generate unlimited supply of cartilage
for repair and regeneration, could have potential
applications everywhere ACI is used now and hope-
fully in more severe cases of joint damage. Also,
anywhere cartilage is required, eg in otorhinolar-
yngological -head and neck surgery, for reconstruc-
tive procedures following head and neck cancer
resection; facial plastic reconstructive procedures
including cosmetic surgery (eg septorhinoplasty,1743-9191/$ - see front matter
doi:10.1016/j.ijsu.2006.01.015congenital malformations); septal perforations;
tracheal reconstruction etc’’.
Intellectual property of the
human genome
A survey of patent records has shown that 20% of
human genes are already patented by biotechnology
companies. The introduction of commercial rights
could limit research into areas, such as diabetes and
obesity, whilst risk the threat of legal action for
ownership of specific genes. In some instances the
rights to certain genes, such as BRCA-1, are claimed
by multiple companies, with around 20 patents
specifying rights of use. Researchers at the Massa-
chusetts Institute of Technology (MIT) calculated the
proportion of human genes that had been patented
by comparing the genetic sequences claimed in US
patents to genes listed in the National Centre for
Biotechnology Information gene database. Mono-
polising genes poses a potential problem for future
medical research. Kyle Jensen, researcher at MIT,
told the IJS: ‘‘4,382 of the known 23, 688 human
genes, have been patented, with over half owned by
private companies. Around 63% of the patents are
assigned to private firms.’’ Dr Murray analyses the
patenting of human genes in the US, although it is
probable that the same genes may have been
patented in Europe.
Jensen and Murray. Science. 2005; 310(5746):
239e40.
Stem cells enable paralysed
mice to walk
Scientists at the Reeve-Irvine Research Centre at
the University of California, USA, have successfully
injected stem cells that heal spinal injuries allowing
10 Newsparalysed mice to walk again. Stem cells (75,000)
were injected above and below the injury site, in
50% of 68 mice. Experiments showed that the stem
cells had formed new neurons and coatings allowing
nerves to signal properly again. Professor Anderson
told the IJS: ‘‘Immediately after the injury, nerve
cells inside die and others lose their ability to pass
on signals. Animals that didn’t get stem cells could
only walk a little, and even though they improved
slightly over the first two to three weeks, they were
really struggling. This kind of work has another
benefit, especially in America where it’s a more
contentious issue, in that it shows people the
potential of using stem cells to treat’’.
New imaging technique predicts
likelihood of bone breakage
Scientists have developed a laser imaging tech-
nique which can fully assess the strength of bones,
a technique the scientists hope can be used to
predict the likelihood of young women developing
osteoporosis. Early action such as increasing
exercise to build up bone mass would prevent the
need for pharmacological interventions with Ri-
sedronate (Actonel). Lead author Dr. Edward
Draper of Imperial College told the IJS: ‘‘Tradition-
ally, the only way to predict bone strength has been
through X-rays, but these can only measure part of
the strength of the bone. Using this new technique
we can get a more complete measurement, allow-
ing us to predict better the risk of fractures as
a result of osteoporosis. We hope we can further
develop this technique, and use it as part of
a national screening programme which hopefully
could be done in any GPs surgery. By identifying the
risk of any problems developing early enough, this
could not only make an enormous difference to the
health of individuals, but could help the NHS by
negating the need for more extreme and costly
interventions later.’’ X-rays can only be used to
measure bone mineral density, which only accounts
for part of the strength. The new Raman spectro-
scopic technique enables measurement of colla-
gen, which also affects bone strength.
Enzyme test for bladder cancer may
expedite diagnosis
Measuring levels of the enzyme telomerase in urine
may be a simple, inexpensive, and accurate way to
detect bladder cancer early, according to Dr
D. Calistri. Diagnosis of bladder cancer is often
delayed because symptoms such as haematuria areintermittent and can be attributed to common
benign disorders, for example, urinary tract in-
fections, prostatitis and renal stones. As a result,
patients with symptoms are often not screened for
cancer with cystoscopy. Telomerase was chosen as
a possible tumour marker because elevated levels
have been found in nearly all human histotypes. In a
study of more than 200 men, the telomeric repeat
amplification protocol (TRAP) achieved a sensitivity
of 90%. The sensitivity of the TRAP test was similar
for low-grade and high-grade tumours.
Sanchini MA et al. JAMA 2005; 294:2052e2056.
Prostate cancer seed placement
Currently, eradication of diseased prostate tissue
involves implanting up to 100 radioactive seeds in
the prostate. Each seed is akin to a grain of rice and
emits radiation in all directions. A hole-studded grid
is mounted over the patient and a hollow needle
used to insert the seeds manually. Directionally
emitting radioactive sources, have been developed
by UW-Madison engineering physics Professor
D. Henderson and medical physics associate Pro-
fessor B. Thomadsen. Their directional seed sources
work by vertically shielding along one side. The
traditional grid has been abandoned in favour of
a robot, which delivers seeds more precisely.
Dr. Thomadsen told the IJS: ‘‘Seeds can now be
implanted, at the boundaries between healthy and
News 11diseased tissue, which targets the radiation to
where it is most needed.’’
British therapeutic stem cell bank
on the horizon
Scientists have calculated that circa 150 stem cell
lines would be needed to establish a therapeutic
stem cell bank in Britain. Stem cells have the
potential to provide new therapies for diseases
ranging from cancer and diabetes to Alzheimer’s
disease and spinal cord injuries. Britain set up the
world’s first stem cell bank in May 2004. Professor
JA. Bradley, of Addenbroke’s Hospital in Cambridge,
told the IJS: ‘‘We found that 150 donors would give
a very good match for about one in five recipients’’.
Like donor organs, stem cells from a therapeutic
bank need to be matched to the recipient minimiz-
ing the risk of rejection and the need for immuno-
suppressant drugs. Unlike a heart, lung, or liver
transplant, which is provided by one donor for one
patient, a single stem cell line could be used for
multiple recipients. The use of embryonic stem cells
is controversial because the master cells that can
form into any cell type in the body are derived from
spare in-vitro fertilization (IVF) embryos. The Brit-
ish Chancellor Gordon Brown announced that the
country would double spending on stem cell re-
search to 100 million pounds over the next 2 years.
Part of this funding will be used to support the stem
cell bank.
Taylor et al. The Lancet 366 (Issue 9502):
2019e2025.
Anti-heparin antibody identifies
increased risk following
cardiac surgery
Elliott Bennett-Guerrero, of Duke University
Medical Center, USA, reports a positive test for
anti-platelet factor 4/heparin antibody before
cardiac surgery nearly doubles the risk of compli-
cations (P¼ 0.0284). In a series of 466 patients,
108 patients had complications that led to death,
or hospitalization of more than 10 days. Fifty-nine
patients (13%) had detectable levels of the anti-
heparin antibody at baseline. Other significantpredictors of outcome were age (P¼ 0.051),
ejection fraction (P¼ 0.005), and preoperative
haematocrit (P¼ 0.0432). All patients were
screened before undergoing elective coronary
artery bypass or valvular surgery. Preoperative
serum levels of the antibody ranged from 0.02
to 3.11 OD units, with a mean of 0.29. The
authors note that a limitation of their study is
that anti-heparin antibodies could represent
a surrogate marker for sicker patients at greater
risk for adverse outcomes. Dr. Bennett-Guerrero
told the IJS: ‘‘Further studies should investigate
whether alternative combinations of intraopera-
tive and postoperative anticoagulation or anti-
platelet therapy are beneficial’’.
Bennett-Guerrero et al. Journal of Thoracic and
Cardiovascular Surgery 2005; 130: 1567e1572.
Differentiation of heart stem cells
discovered
A team of scientists at the Gladstone Institute of
Cardiovascular Disease (GICD) has identified
a key factor in heart development that could
advance gene therapy for treating cardiac disor-
ders. In the study, using Drosophila fly embryos
as model systems, the research team demon-
strated that a form of miRNA known as miR-1,
helps in determining heart stem cells in the early
embryonic stage. They further showed that miR-
1 helps in maintenance of heart precursors
in later embryonic stages. In addition, miR-1
can repress the ligand Delta, which otherwise
binds to its receptor, Notch. Importantly, the
binding of Delta and Notch mediates develop-
ment of many kinds of tissues and is involved
in differentiation of cardiac stem cells into mus-
cle cells. They hope that the findings will be
used in future to target gene-mediated therapies
preventing early heart developmental problems.
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